Lexaria Bioscience LEXX
NASDAQ LEXX
$2.88 -0.21 (-6.80%)
At close: Oct 2, 2026 · 4:00 PM EDT

Lexaria Bioscience (LEXX) Gains from Sales and Divestitures (2020 - 2022)

Updated

Lexaria Bioscience's Gains from Sales and Divestitures was -$1.53 million in fiscal Q4 2022 (quarter ended Aug 31, 2022).

Analysis

Lexaria Bioscience (LEXX) Gains from Sales and Divestitures (2020 - 2022) Analysis & Trends

For FY2022 (ended Aug 31, 2022), Gains from Sales and Divestitures at Lexaria Bioscience came in at -$7,926.

  • In earlier fiscal years, Gains from Sales and Divestitures was $1.52 million in FY2021.
  • The fiscal Q4 2022 figure marks the highest quarterly Gains from Sales and Divestitures since fiscal Q2 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Lexaria Bioscience 3.04 Mn -12.61 Mn -
Historic Data

Historic Data

Download Data
DateValue
Aug 31, 2022 -1.53 Mn
Feb 28, 2021 1.52 Mn
Aug 31, 2020 18,198.00
May 31, 2020 -18,198.00
API Access

Lexaria Bioscience Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=LEXX&period=max&api_key=YOUR_API_KEY